Registration will be closed at 4:00 PM on Thursday, April 27, 2023.
After the registration is closed, please visit on-site to register for in-person participation. For virtual attendance, please email ccpd@mednet.ucla.edu or call 310-794-2620 to register. 

For the past 40 years, The Annual Seminar Frontiers of Rheumatology, has honored the memory of Carl M. Pearson, MD, the founding chief of Rheumatology at UCLA. This event gathers distinguished faculty for three days of interactions, presentations and educational discussions with participants, of current topics, recent advances and impending progress of importance to physicians and other providers of care to patients with autoimmune and musculoskeletal conditions. The course has been well reviewed by participants and by visiting faculty who enjoy the relaxed atmosphere, challenging queries from participants and many opportunities for interactions. Many have repeatedly returned to subsequent seminars. Participants record their opinions about the quality of each presentation and of the overall course each year. In 2022, there were 145 attendees. 96.5% thought the program taught or verified important information and a gratifyingly high 98.85% felt the information would impact their practices. 99% thought the program fulfilled the course objectives and 100% would recommend the course to others. Lastly, 93% felt an annual update is needed.

Participants also record their suggestions for future topics and speakers. Their suggestions are used by the organizers, along with comments from the faculty and knowledge of current literature and areas of need, to develop each year’s program. The basic purpose of the seminars is to maintain and improve the skills of the participants and to improve the care and outcomes of their patients.

40th Carl M. Pearson Memorial Symposium Frontiers of Rheumatology 2023 Brochure (PDF)

Target Audience

This program is intended to provide rheumatologists, interested physicians, health care professionals, and rheumatology fellows with the most current information and insights on treatment of rheumatic disease. Interaction between participants and faculty members is emphasized.

REGISTRATION INFORMATION

Registration will be closed at 4:00 PM on Thursday, April 27, 2023.
After the registration is closed, please visit on-site to register for in-person participation. For virtual attendance, please email ccpd@mednet.ucla.edu or call 310-794-2620 to register. 

In-person attendees will be provided breakfast and catering at the meeting site. The UCLA Frontiers of Rheumatology 2023 will also be available through a live virtual meeting web platform. Attendees who choose to attend the live virtual activity will receive a virtual meeting link and password to access the live virtual conference. All registrants (live or virtual) will be provided the opportunity to review recorded sessions up to 3 weeks following the conference.

Course Fees

• $350 MD, PhD – Live In-Person Participant
• $350 MD, PhD – Live Virtual Participant via zoom
• $150 RN – Live In-Person Participant
• $150 RN – Live Virtual Participant via zoom
• $80 Trainees/Fellows – Live In-Person Participant
• $80 Trainees/Fellows – Live Virtual Participant via zoom

Refunds

Cancellations must be received by email to ccpd@mednet.ucla.edu by Friday, March 31, 2023 and will be subject to a $75 processing fee. No refunds will be granted after that date. If, for any reason, the course must be cancelled, discontinued, or rescheduled, a full refund will be provided.

Questions

If you have questions about enrollment, please call (310) 794-2620 or email ccpd@mednet.ucla.edu.

ACCOMMODATIONS

A limited block of rooms has been reserved at the Marina del Rey Marriott for seminar participants at a special conference rate starting at $249 per night for single/double occupancy. Confirmation of reservations received after Friday, April 7, 2023 is subject to availability. To reserve a room call (800) 228-9290 or (310) 301-3000. Make sure to mention the UCLA Rheumatology Course when calling in your reservations.

EXHIBITOR INFORMATION

Please email ccpd@mednet.ucla.edu.

OBJECTIVES

Frontiers of Rheumatology’s objective is to update the learner’s current knowledge in rheumatology, focusing on the practical clinical perspective.
In addition to lectures and extensive question-and-answer periods, casual exchanges will provide many opportunities for faculty and participants to interact and discuss clinically important topics. Upon completion of this program, participants should be able to:

• Learn about the newest updates in the understanding of and treating of rheumatoid arthritis and gout.
• Increase their understanding of the effects of the drugs used in rheumatology during pregnancy.
• Obtain a deeper understanding of the effects of the recent Supreme Court decision regarding abortion on their practice.
• Gain insights about the neurological manifestations that are a part of Sjogren’s syndrome and how to treat it.
• Examine the newest developments in the diagnosis and treatment of central nervous system SLE
• Improve their understanding on what is new in VEXAS.
• Describe the rapidly changing understanding of psoriatic arthritis and its treatment.
• Understand the complexities of lung disease in rheumatology.

ACCREDITATION

The David Geffen School of Medicine at UCLA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The David Geffen School of Medicine at UCLA, designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The California State Board of Registered Nursing accepts courses approved for the AMA PRA Category 1 Credits™ as meeting the continuing education requirements for license renewal. Nurses from states other than California should inquire with their local State Board for specific continuing education policies.

DISCLOSURES

The FDA has issued a concept paper that classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is “truly independent” and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program’s participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the provider adequately manage all identified potential conflicts of interest prior to the program. UCLA fully endorses the letter and spirit of these concepts.